{"id":744886,"date":"2014-12-08T07:00:00","date_gmt":"2014-12-08T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/"},"modified":"2023-03-22T00:04:48","modified_gmt":"2023-03-22T04:04:48","slug":"merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/","title":{"rendered":"Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash"},"content":{"rendered":"<p class=\"bwalignc\">       Acquisition Augments Merck\u2019s Strong Foundation and Opportunity for        Growth in Hospital Acute Care Market     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the<br \/>\n      companies have entered into a definitive agreement under which Merck<br \/>\n      will acquire Cubist for $102 per share in cash, which represents a 35<br \/>\n      percent premium to Cubist\u2019s average stock price for the most recent five<br \/>\n      trading days.\n    <\/p>\n<p>\n      Unanimously approved by the boards of directors of both companies, the<br \/>\n      transaction has an equity valuation of $8.4 billion and will also<br \/>\n      include $1.1 billion in net debt (based on projected cash balances) and<br \/>\n      other considerations for a total transaction value of approximately $9.5<br \/>\n      billion.\n    <\/p>\n<p>\n      \u201cCubist is a global leader in antibiotics and has built a strong<br \/>\n      portfolio of both marketed and late-stage pipeline medicines,\u201d said<br \/>\n      Kenneth C. Frazier, chairman and chief executive officer, Merck.<br \/>\n      \u201cCombining this expertise with Merck\u2019s strong capabilities and global<br \/>\n      reach will enable us to create a stronger position in hospital acute<br \/>\n      care while addressing critical areas of unmet medical need, such as<br \/>\n      antibiotic resistance.\u201d\n    <\/p>\n<p>\n      \u201cCombining with Merck is an exciting opportunity to accelerate Cubist\u2019s<br \/>\n      established leadership in antibiotics and deliver significant, certain<br \/>\n      and immediate value to shareholders,\u201d said Michael Bonney, chief<br \/>\n      executive officer, Cubist. \u201cWe have a deep respect for Merck, and it is<br \/>\n      clear that they share our commitment to addressing the growing, global<br \/>\n      problem we are facing in combating antibiotic-resistant bacteria. Under<br \/>\n      Merck\u2019s robust commercial platform, global reach and scientific<br \/>\n      expertise, we believe Cubist&#8217;s programs can thrive. We\u2019re proud of the<br \/>\n      company that our team has built and are confident that Cubist&#8217;s<br \/>\n      important mission and focus on significant unmet medical needs will<br \/>\n      continue.\u201d\n    <\/p>\n<p>\n      For more than 20 years, Cubist has been committed to global public<br \/>\n      health through the discovery, development and supply of antibiotics to<br \/>\n      treat serious and potentially life-threatening infections caused by a<br \/>\n      broad range of increasingly drug-resistant bacteria. Cubist\u2019s antibiotic<br \/>\n      CUBICIN<sup>\u00ae<\/sup>, the only approved once-a-day therapy for both S.<br \/>\n      aureus bacteremia and complicated skin and skin structure infections<br \/>\n      (cSSSI), has been used to treat more than two million patients and<br \/>\n      continues to be an important therapy in the acute care environment.<br \/>\n      Cubist\u2019s in-line and late-stage pipeline of anti-infective medicines,<br \/>\n      including ZERBAXA<sup>\u2122<\/sup> which is pending approval from the U.S.<br \/>\n      Food and Drug Administration, will enhance Merck\u2019s hospital acute care<br \/>\n      business in a variety of therapeutic areas, including Gram-positive and<br \/>\n      Gram-negative multi-drug resistant infections.\n    <\/p>\n<p>\n      The acquisition of Cubist creates strong fundamental value with return<br \/>\n      on capital in excess of Merck&#8217;s hurdle rate within a few years of<br \/>\n      closing. Merck expects the acquisition to add more than $1 billion of<br \/>\n      revenue to its 2015 base. While the transaction will be neutral to<br \/>\n      non-GAAP EPS in 2015, Merck expects it to be significantly accretive to<br \/>\n      non-GAAP EPS in 2016 and beyond. The acquisition will be accretive to<br \/>\n      both Merck\u2019s sales and earnings growth.\n    <\/p>\n<p>\n      Cubist complements Merck\u2019s strategy and the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fcorporate-news%2Fmerck-announces-global-initiative-sharpen-commercial-and-rd-focus&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=global+initiative&amp;index=1&amp;md5=d60c39499bcc6e6ccd884c18e7588053\" rel=\"nofollow\">global<br \/>\n      initiative<\/a> Merck launched last year, particularly in the area of<br \/>\n      sharpening its commercial focus on key therapeutic areas that have the<br \/>\n      potential to deliver the greatest return on investment. With the<br \/>\n      company\u2019s long-standing leadership in anti-infectives as well as its<br \/>\n      customer-focused operating model, Merck identified the hospital acute<br \/>\n      care segment as one of the company\u2019s key priority areas in which it<br \/>\n      believes it can have the greatest impact in addressing significant unmet<br \/>\n      medical needs while delivering the greatest value to customers and<br \/>\n      society.\n    <\/p>\n<p>\n      Merck strategically focused on acute care within the larger hospital<br \/>\n      setting as a top priority because of the significant unmet need and the<br \/>\n      unique opportunities for Merck to improve patient care and manage costs<br \/>\n      in this setting with its in-line portfolio, promising pipeline and its<br \/>\n      customer capabilities.\n    <\/p>\n<p>\n      Hospitals are a central hub for healthcare delivery around the world and<br \/>\n      currently represent 25 percent of overall healthcare spend. Merck<br \/>\n      believes now is an optimal time to significantly grow its hospital acute<br \/>\n      care presence because of the positive regulatory and reimbursement<br \/>\n      trends in the hospital setting and the increasingly important role that<br \/>\n      hospitals are expected to provide in healthcare overall.\n    <\/p>\n<p>\n      For the first three quarters of 2014 compared to 2013, Merck\u2019s hospital<br \/>\n      acute care portfolio grew by more than 10 percent, excluding the impact<br \/>\n      of foreign exchange. Key products in Merck\u2019s hospital acute care<br \/>\n      portfolio include several antibiotics and antifungals, as well as BRIDION<sup>\u00ae<\/sup><br \/>\n      (sugammadex), which is marketed outside the United States and is<br \/>\n      currently under regulatory review in the United States. In addition,<br \/>\n      Merck has continued to invest in its hospital acute care pipeline and<br \/>\n      has several candidates, including actoxumab\/bezlotoxumab (MK-3415A), an<br \/>\n      investigational combination of therapeutic antibodies targeting two <i>C.difficile<br \/>\n      <\/i>pathogenic toxins (A and B), which is being evaluated in clinical<br \/>\n      trials for the prevention of recurrence of <i>C.difficile<\/i> infection;<br \/>\n      and relebactam (MK-7655), an investigational class A and C <i>beta<\/i>-lactamase<br \/>\n      inhibitor being evaluated in clinical trials for the treatment of severe<br \/>\n      bacterial infections.\n    <\/p>\n<p>\n      Under the terms of the agreement, Merck, through a subsidiary, will<br \/>\n      initiate a tender offer to acquire all outstanding shares of Cubist<br \/>\n      Pharmaceuticals, Inc. The closing of the tender offer will be subject to<br \/>\n      certain conditions, including the tender of shares representing at least<br \/>\n      a majority of the total number of Cubist\u2019s outstanding shares (assuming<br \/>\n      the exercise of all options), the expiration of the waiting period under<br \/>\n      the Hart-Scott-Rodino Antitrust Improvements Act and other customary<br \/>\n      conditions. Upon the completion of the tender offer, Merck will acquire<br \/>\n      all remaining shares through a second-step merger without the need for a<br \/>\n      stockholder vote under Delaware law. The companies expect the<br \/>\n      transaction to close in the first quarter of 2015.\n    <\/p>\n<p>\n      <b>Important Information about the Tender Offer<\/b>\n    <\/p>\n<p>\n      The tender offer for the outstanding shares of Cubist has not yet<br \/>\n      commenced. This news release is for informational purposes only and is<br \/>\n      neither an offer to purchase nor a solicitation of an offer to sell<br \/>\n      shares, nor is it a substitute for the tender offer materials that Merck<br \/>\n      and its subsidiary will file with the Securities and Exchange Commission<br \/>\n      (SEC). At the time the planned tender offer is commenced, a tender offer<br \/>\n      statement on Schedule TO will be filed by Merck with the SEC, and Cubist<br \/>\n      will file a solicitation\/recommendation statement on Schedule 14D-9 with<br \/>\n      respect to the tender offer. The tender offer materials (including an<br \/>\n      offer to purchase, a related letter of transmittal and other tender<br \/>\n      offer documents) and the solicitation\/recommendation statement will<br \/>\n      contain important information that holders of Cubist common stock shares<br \/>\n      are urged to read carefully when they become available, as each may be<br \/>\n      amended or supplemented from time to time and because they will contain<br \/>\n      important information that holders of shares of Cubist common stock<br \/>\n      should consider before making any decision regarding tendering their<br \/>\n      shares. The tender offer materials will be made available to Cubist\u2019s<br \/>\n      stockholders at no expense to them. In addition, all of those materials<br \/>\n      (and other tender offer documents filed with the SEC) will be made<br \/>\n      available at no charge on the SEC\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=dd4f21de83d8f123c699fa1a7537cb77\" rel=\"nofollow\">www.sec.gov<\/a>.<br \/>\n      Additional copies of the tender offer materials may be obtained at no<br \/>\n      charge by contacting Merck at 2000 Galloping Hill Road, Kenilworth,<br \/>\n      N.J., 07033 or by phoning (908) 740-4000. In addition, Merck and Cubist<br \/>\n      file annual, quarterly and current reports and other information with<br \/>\n      the SEC. You may read and copy any reports or other information filed by<br \/>\n      Merck or Cubist at the SEC public reference room at 100 F Street, N.E.,<br \/>\n      Washington, D.C., 20549. For further information on the SEC public<br \/>\n      reference room, please call 1-800-SEC-0330. Merck\u2019s and Cubist\u2019s filings<br \/>\n      with the SEC are also available to the public from commercial<br \/>\n      document-retrieval services and at the SEC\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=067fbefd08750cc9e61c6860f9bc01e0\" rel=\"nofollow\">www.sec.gov<\/a>.\n    <\/p>\n<p>\n      In this transaction, J.P. Morgan and Deutsche Bank served as financial<br \/>\n      advisors to Merck, and Hughes Hubbard &amp; Reed LLP and Baker &amp; McKenzie<br \/>\n      served as its legal advisors. Morgan Stanley &amp; Co. LLC and Goldman,<br \/>\n      Sachs &amp; Co. served as financial advisors to Cubist, and Ropes &amp; Gray<br \/>\n      served as its legal advisor.\n    <\/p>\n<p>\n      <b>Investor Briefing Call<\/b>\n    <\/p>\n<p>\n      Merck will hold a call with institutional investors and analysts at 8:00<br \/>\n      a.m. EST today, Dec. 8, 2014. Institutional investors and analysts can<br \/>\n      participate in the call by dialing (706) 758-9927 or (877) 381-5782 and<br \/>\n      using ID code number 48773641. Members of the media are invited to<br \/>\n      monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using<br \/>\n      ID code number 48773641. Journalists who wish to ask questions are<br \/>\n      requested to contact a member of Merck\u2019s Media Relations team at the<br \/>\n      conclusion of the call.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=b9b88e85cf6b487aaa38f9cba6219fc0\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=090df8a13d2bdbe091a06873eb3eccd5\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=90711077642a19f9e24a155ae41943f8\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=ecdff2ffffe5658fbe037fc9371dde47\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Forward-looking statements<br \/>\n      include statements regarding the timing and closing of the tender offer<br \/>\n      and the merger transactions, the ability of Merck to complete the<br \/>\n      transactions considering the various closing conditions, and any<br \/>\n      assumptions underlying any of the foregoing. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; the exposure to litigation, including patent<br \/>\n      litigation, and\/or regulatory actions; timing of the tender offer and<br \/>\n      merger; uncertainties as to how many Cubist stockholders will tender<br \/>\n      shares in the tender offer; the possibility that competing offer may be<br \/>\n      made; the possibility that various closing conditions to transactions<br \/>\n      may not be satisfied or waived, including that a governmental entity may<br \/>\n      prohibit, delay or refuse to grant approval for the consummation of the<br \/>\n      transactions; or that a material adverse effect occurs with respect to<br \/>\n      Cubist.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the SEC available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=0dd2c456e8a08d729890c3745693c4c1\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>About Cubist<\/b>\n    <\/p>\n<p>\n      Cubist Pharmaceuticals, Inc. is a global biopharmaceutical company<br \/>\n      focused on the research, development, and commercialization of<br \/>\n      pharmaceutical products that address significant unmet medical needs in<br \/>\n      the acute care environment. Cubist\u2019s corporate headquarters is based in<br \/>\n      Lexington, Massachusetts, with international headquarters located in<br \/>\n      Zurich, Switzerland. Additional information can be found at Cubist\u2019s web<br \/>\n      site at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cubist.com&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=www.cubist.com&amp;index=9&amp;md5=fbbf7ee77a4debad976901c5be292d4e\" rel=\"nofollow\">www.cubist.com<\/a>.<br \/>\n      Also, connect with Cubist on Twitter <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fcubistbiopharma&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=%40cubistbiopharma&amp;index=10&amp;md5=97574ae3f7f5701ca88ca5d7895c227b\" rel=\"nofollow\">@cubistbiopharma<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FCubistCareers&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=%40cubistcareers&amp;index=11&amp;md5=ecfaf8add05e8dce15fc045af16de053\" rel=\"nofollow\">@cubistcareers<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fcubist-pharmaceuticals&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=12&amp;md5=be1bf56c85d7deaa14eace4579dfaec0\" rel=\"nofollow\">LinkedIn<\/a>,<br \/>\n      or <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fuser%2FCubistBioPharma&amp;esheet=50998231&amp;newsitemid=20141208005433&amp;lan=en-US&amp;anchor=YouTube&amp;index=13&amp;md5=89a7bbf3c0c98f281bb186230b8ab60c\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Cubist Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This press release contains forward-looking statements. Any statements<br \/>\n      contained herein which do not describe historical facts, including but<br \/>\n      not limited to, statements regarding the timing and closing of the<br \/>\n      tender offer and the merger transactions and the ability of Cubist to<br \/>\n      complete the transaction are forward-looking statements which involve<br \/>\n      risks and uncertainties that could cause actual results to differ<br \/>\n      materially from those discussed in such forward-looking statements. Such<br \/>\n      risks and uncertainties include, among others: the risk that Cubist<br \/>\n      stockholders will not tender shares in the tender offer; the possibility<br \/>\n      that competing offers may be made; the possibility that various closing<br \/>\n      conditions may not be satisfied or waived; or that a material adverse<br \/>\n      effect occurs with respect to Cubist; and those additional factors<br \/>\n      discussed in Cubist\u2019s most recent Annual Report on Form 10-K and<br \/>\n      subsequent Quarterly Reports on Form 10-Q filed with the SEC. Cubist<br \/>\n      cautions investors not to place considerable reliance on the<br \/>\n      forward-looking statements contained in this press release. These<br \/>\n      forward-looking statements speak only as of the date of this document,<br \/>\n      and Cubist undertakes no obligation to update or revise any of these<br \/>\n      statements.\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141208005433r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20141208005433\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/multimedia\/home\/20141208005433\/en\/<\/a><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Lainie Keller, 908-406-1459<br \/>or<br \/>Steve        Cragle, 908-740-1801<br \/>or<br \/>Investor Contacts:<br \/>Joe Romanelli,        908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879<br \/>or<br \/>Cubist<br \/>Media        Contact:<br \/>Julie DiCarlo, 781-860-8063<br \/>or<br \/>Investor Contact:<br \/>Eileen        C. McIntyre, 781-860-8100     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acquisition Augments Merck\u2019s Strong Foundation and Opportunity for Growth in Hospital Acute Care Market Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist\u2019s average stock price for the most recent five trading days. Unanimously approved by the boards of directors of both companies, the transaction has an equity valuation of $8.4 billion and will also include $1.1 billion in net debt (based on projected cash balances) and other considerations for a total transaction value of approximately $9.5 billion. \u201cCubist is a global leader in antibiotics and has built a strong portfolio of both marketed and late-stage pipeline medicines,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cCombining this expertise with Merck\u2019s<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744886","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Acquisition Augments Merck\u2019s Strong Foundation and Opportunity for Growth in Hospital Acute Care Market Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist\u2019s average stock price for the most recent five trading days. Unanimously approved by the boards of directors of both companies, the transaction has an equity valuation of $8.4 billion and will also include $1.1 billion in net debt (based on projected cash balances) and other considerations for a total transaction value of approximately $9.5 billion. \u201cCubist is a global leader in antibiotics and has built a strong portfolio of both marketed and late-stage pipeline medicines,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cCombining this expertise with Merck\u2019s\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141208005433r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\\\/\",\"name\":\"Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141208005433r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2014-12-08T07:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141208005433r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141208005433r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash - Merck.com","og_description":"Acquisition Augments Merck\u2019s Strong Foundation and Opportunity for Growth in Hospital Acute Care Market Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist\u2019s average stock price for the most recent five trading days. Unanimously approved by the boards of directors of both companies, the transaction has an equity valuation of $8.4 billion and will also include $1.1 billion in net debt (based on projected cash balances) and other considerations for a total transaction value of approximately $9.5 billion. \u201cCubist is a global leader in antibiotics and has built a strong portfolio of both marketed and late-stage pipeline medicines,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \u201cCombining this expertise with Merck\u2019s","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:48+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141208005433r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/","name":"Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141208005433r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2014-12-08T07:00:00+00:00","dateModified":"2023-03-22T04:04:48+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141208005433r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141208005433r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"c6102897-c799-40e2-bdb1-890b4013584b","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/12\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/12\/1\/Cubist_Logo-5B1-5D.jpg","size":"7658","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-to-Acquire-Cubist-Pharmaceuticals-for-102-Per-Share-in-Cash-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744886\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744886"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}